{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:19Z","timestamp":1793367139133,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","award":["IG 2024\\u2014ID30919"],"award-info":[{"award-number":["IG 2024\\u2014ID30919"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annonc.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:20:51Z","timestamp":1789662051000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive\/HER2-negative breast cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3585","authenticated-orcid":false,"given":"L.","family":"Licata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7444-8578","authenticated-orcid":false,"given":"M.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zanibelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-7902","authenticated-orcid":false,"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Patan\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"M.","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9542-2884","authenticated-orcid":false,"given":"M.M.","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8379-1497","authenticated-orcid":false,"given":"G.","family":"Notini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-361X","authenticated-orcid":false,"given":"G.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"L.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.005_bib2","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study","volume":"8","author":"Heer","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp0708307","article-title":"\u201cWesternizing\u201d women\u2019s risks? Breast cancer in lower-income countries","volume":"358","author":"Porter","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"27","key":"10.1016\/j.annonc.2026.09.005_bib5","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib6","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/annonc\/mdq072","article-title":"Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer","volume":"21","author":"Cancello","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib7","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s00268-011-1071-1","article-title":"Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study","volume":"35","author":"Kim","year":"2011","journal-title":"World J Surg"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.005_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.09.005_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13058-015-0618-8","article-title":"The molecular landscape of premenopausal breast cancer","volume":"17","author":"Liao","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","article-title":"Genomic characterisation of hormone receptor-positive breast cancer arising in very young women","volume":"34","author":"Luen","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105764","article-title":"Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer","volume":"10","author":"Walbaum","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib12","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-21-2572","article-title":"Somatic and germline genomic alterations in very young women with breast cancer","volume":"28","author":"Waks","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jamaoncol.2015.5941","article-title":"BRCA1 and BRCA2 mutation testing in young women with breast cancer","volume":"2","author":"Rosenberg","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.annonc.2024.06.009","article-title":"Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers","volume":"35","author":"Arecco","year":"2024","journal-title":"Ann Oncol"},{"issue":"9472","key":"10.1016\/j.annonc.2026.09.005_bib15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"10540","key":"10.1016\/j.annonc.2026.09.005_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(26)00313-2","article-title":"Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials","volume":"407","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: long-term health consequences","volume":"65","author":"Shuster","year":"2010","journal-title":"Maturitas"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib18","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.005_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.09.005_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.annonc.2026.05.704","article-title":"Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer","volume":"37","author":"Francis","year":"2026","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.005_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.annonc.2026.09.005_bib26","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1200\/JCO.23.00557","article-title":"Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial","volume":"41","author":"Baek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2025.43.16_suppl.506","article-title":"Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor\u2013positive breast cancer: results from the ASTRRA trial","volume":"43","author":"Ryu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.005_bib28","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2023.41.16_suppl.504","article-title":"Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: a secondary analysis of the SOFT trial","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamaoncol.2024.3044","article-title":"Breast cancer index in premenopausal women with early-stage hormone receptor-positive breast cancer","volume":"10","author":"O\u2019Regan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40931","article-title":"Assessment of adjuvant endocrine therapy with ovarian function suppression by breast cancer index","volume":"8","author":"O\u2019Regan","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2026.09.005_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116266","article-title":"Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: an exploratory analysis of two prospective studies","volume":"236","author":"Nardin","year":"2026","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106079","article-title":"Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study","volume":"11","author":"Valenza","year":"2026","journal-title":"ESMO Open"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.005_bib34","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-024-00680-0","article-title":"Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy","volume":"10","author":"Tesch","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10549-026-07960-2","article-title":"Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis","volume":"217","author":"de Liz","year":"2026","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.005_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/OP-24-00502","article-title":"Clinical management of ovarian function suppression in premenopausal women with breast cancer: a survey of members of ASCO","volume":"21","author":"Kelly","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1470-2045(11)70270-4","article-title":"Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8\u00b71 years median follow-up","volume":"12","author":"Regan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/JCO.2025.43.16_suppl.505","article-title":"15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS","volume":"43","author":"Francis","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.005_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231151840","article-title":"Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer","volume":"15","author":"Paluch-Shimon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2025.43.16_suppl.516","article-title":"Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: analysis across menopausal status and age","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib43","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","article-title":"Clinical utility of gene-expression signatures in early stage breast cancer","volume":"14","author":"Kwa","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-020-00188-3","article-title":"Clinical utility of genomic signatures in young breast cancer patients: a systematic review","volume":"6","author":"Villarreal-Garza","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.19.01959","article-title":"Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-positive\/HER2-negative breast cancer","volume":"38","author":"Poorvu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.005_bib47","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.annonc.2026.09.005_bib48","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-023-07227-0","article-title":"Real-world use of multigene signatures in early breast cancer: differences to clinical trials","volume":"205","author":"Licata","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.005_bib50","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41523-021-00264-2","article-title":"NRG Oncology\/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab","volume":"7","author":"Ganz","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10384","key":"10.1016\/j.annonc.2026.09.005_bib53","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib54","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.annonc.2025.08.002","article-title":"Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer","volume":"36","author":"Chen","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.005_bib55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.annonc.2025.12.013","article-title":"A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding \u201cImpact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer\u201d by Chen et al","volume":"37","author":"Gluz","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41523-022-00492-0","article-title":"Molecular differences between younger versus older ER-positive and HER2-negative breast cancers","volume":"8","author":"Qing","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-015-3479-z","article-title":"Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials","volume":"152","author":"Loibl","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib58","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41416-023-02477-7","article-title":"Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy","volume":"129","author":"Licata","year":"2023","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib59","first-page":"1220","article-title":"Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)","volume":"37","author":"Kalinsky","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib61","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2026.44.16_suppl.500","article-title":"First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer","volume":"44","author":"Stein","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-013-2416-2","article-title":"PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer","volume":"138","author":"Mart\u00edn","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw050","article-title":"Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others","volume":"108","author":"Bartlett","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib66","first-page":"GS1","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA breast cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.005_bib67","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"10503","key":"10.1016\/j.annonc.2026.09.005_bib68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.annonc.2026.09.005_bib69","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/1078-0432.CCR-18-0162","article-title":"Targeted therapy for premenopausal women with HR+, HER2\u2212 advanced breast cancer: focus on special considerations and latest advances","volume":"24","author":"Bardia","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib70","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"9869","key":"10.1016\/j.annonc.2026.09.005_bib71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"suppl 18","key":"10.1016\/j.annonc.2026.09.005_bib72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/annonc\/mds330","article-title":"Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole","volume":"24","author":"Goss","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib74","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-024-07509-1","article-title":"Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy","volume":"209","author":"Ito","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO-25-01660","article-title":"Extended endocrine therapy following 5 years of adjuvant luteinizing hormone-releasing hormone agonist in premenopausal patients with node-positive, hormone receptor-positive breast cancer: a cohort study","volume":"44","author":"Valenza","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI109475","article-title":"Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women","volume":"64","author":"Sherman","year":"1979","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.005_bib77","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.005_bib79","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib80","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/s41598-020-61648-1","article-title":"Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.annonc.2026.09.005_bib81","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.annonc.2026.09.005_bib82","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.23.02643","article-title":"Social characteristics and adherence to adjuvant endocrine therapy in premenopausal women with breast cancer","volume":"42","author":"Schmidt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10430","key":"10.1016\/j.annonc.2026.09.005_bib83","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(23)02800-3","article-title":"Optimising health after early menopause","volume":"403","author":"Mishra","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.005_bib84","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2026.09.005_bib85","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials","volume":"35","author":"Saha","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.005_bib86","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2023.41.16_suppl.551","article-title":"Influence of adherence to adjuvant endocrine therapy in early breast cancer: results from a large German real-world claims data analysis","volume":"41","author":"Dannehl","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.09.005_bib87","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.24.01131","article-title":"Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study","volume":"43","author":"Dumas","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.005_bib88","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1158\/1078-0432.CCR-20-3974","article-title":"Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women","volume":"27","author":"Collin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.09.005_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103493","article-title":"Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study","volume":"88","author":"Eriksson Bergman","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib90","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/annonc\/mdt037","article-title":"Aromatase inhibitor-induced arthralgia: a review","volume":"24","author":"Niravath","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib91","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2009.23.4708","article-title":"Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer","volume":"28","author":"Crew","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib92","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jama.2018.8907","article-title":"Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial","volume":"320","author":"Hershman","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib93","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202","volume":"36","author":"Henry","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib94","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1097\/NCC.0000000000000409","article-title":"Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis","volume":"40","author":"Yang","year":"2017","journal-title":"Cancer Nurs"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.005_bib95","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib96","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of The North American Menopause Society","volume":"30","author":"Shufelt","year":"2023","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib97","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2026.09.005_bib98","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2012.43.0116","article-title":"Cancer- and cancer treatment-associated cognitive change: an update on the state of the science","volume":"30","author":"Ahles","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.005_bib99","doi-asserted-by":"crossref","first-page":"e848","DOI":"10.1093\/oncolo\/oyae090","article-title":"Cognitive impairment following breast cancer treatments: an umbrella review","volume":"29","author":"Oliva","year":"2024","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib100","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","article-title":"ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)","volume":"31","author":"Paluch-Shimon","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib101","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaoncol.2025.5220","article-title":"Cognitive impairment and chemoendocrine vs endocrine therapy in pre- and postmenopausal women: a secondary analysis of the RxPONDER randomized clinical trial","volume":"12","author":"Kang","year":"2026","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2026.09.005_bib102","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.19.01866","article-title":"Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx","volume":"38","author":"Wagner","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.005_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-26-517676","article-title":"Assessment and management of cancer-related cognitive impairment","volume":"46","author":"Cheung","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib104","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/OP-24-00953","article-title":"Cancer-related cognitive impairment: a practical guide for oncologists","volume":"21","author":"Zhang","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.005_bib105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/pon.3707","article-title":"Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial","volume":"24","author":"Derry","year":"2015","journal-title":"Psychooncology"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijchp.2025.100576","article-title":"Effects of mindfulness-based interventions on cognitive impairment in patients with cancer: a systematic review and meta-analysis","volume":"25","author":"Jiang","year":"2025","journal-title":"Int J Clin Health Psychol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib107","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/jnci\/djaf059","article-title":"Comparative effectiveness of various nonpharmacological interventions, including traditional Chinese medicine-based interventions for cancer-related cognitive impairment: a comprehensive network meta-analysis","volume":"117","author":"Ho","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib108","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib109","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.09.005_bib111","article-title":"Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy","volume":"43","author":"Lambertini","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib112","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/13697137.2023.2167596","article-title":"Vaginal oxygen plus hyaluronic acid on genito-urinary symptoms of breast cancer survivors","volume":"26","author":"Massarotti","year":"2023","journal-title":"Climacteric"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib113","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.2016.69.6021","article-title":"Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial","volume":"35","author":"Hummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.005_bib115","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study","volume":"114","author":"Cold","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib116","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2026.09.005_bib117","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.01171","article-title":"Electronic health interventions for patients with breast cancer: systematic review and meta-analyses","volume":"40","author":"Singleton","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.005_bib118","first-page":"GS3","article-title":"Abstract GS3-03: Randomized controlled trial of Young, Empowered & Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors","volume":"32","author":"Partridge","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib119","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17873","article-title":"Remote monitoring app for endocrine therapy adherence among patients with early-stage breast cancer: a randomized clinical trial","volume":"7","author":"Graetz","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annonc.2026.09.005_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103866","article-title":"Digital illiteracy and access to remote patient monitoring in oncology: a multicentre study of healthcare providers\u2019 perceptions and patient-reported digital literacy","volume":"94","author":"Prospero","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.005_bib121","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000501473","article-title":"Tamoxifen exposure during pregnancy: a systematic review and three more cases","volume":"15","author":"Buonomo","year":"2020","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.annonc.2026.09.005_bib122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.breast.2018.08.099","article-title":"The BCY3\/BCC 2017 survey on physicians\u2019 knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients","volume":"42","author":"Lambertini","year":"2018","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.005_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102031","article-title":"Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis","volume":"8","author":"Arecco","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2023.25463","article-title":"Pregnancy after breast cancer in young BRCA carriers: an international hospital-based cohort study","volume":"331","author":"Lambertini","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2026.09.005_bib125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.breast.2019.07.001","article-title":"Fertility concerns, preservation strategies and quality of life in young women with breast cancer: baseline results from an ongoing prospective cohort study in selected European centers","volume":"47","author":"Ruggeri","year":"2019","journal-title":"Breast"},{"issue":"18","key":"10.1016\/j.annonc.2026.09.005_bib126","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","article-title":"Interrupting endocrine therapy to attempt pregnancy after breast cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.005_bib127","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.annonc.2026.05.699","article-title":"Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial","volume":"37","author":"Pagani","year":"2026","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2026.09.005_bib128","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.23.02292","article-title":"Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy","volume":"42","author":"Azim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.09.005_bib129","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO-24-02697","article-title":"Breastfeeding after hormone receptor-positive breast cancer: results from the POSITIVE Trial","volume":"43","author":"Peccatori","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.005_bib131","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.005_bib132","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14511","article-title":"Clinicians\u2019 perspectives on barriers to discussing infertility and fertility preservation with young women with cancer","volume":"2","author":"Covelli","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.005_bib133","first-page":"GS03","article-title":"Abstract GS3-02: Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study","volume":"32","author":"Lambertini","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2026.09.005_bib134","volume":"36","author":"Llombart Cussac","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.005_bib135","first-page":"PD10","article-title":"Abstract PD10-01: Elacestrant alone or in combination with triptorelin in premenopausal women with ER+\/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- Premi\u00c8Re trial","volume":"32","author":"Bellet","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.005_bib136","article-title":"LBA2: A window-of-opportunity (WOO) trial of giredestrant +\/- LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+\/HER2- early breast cancer: PREcoopERA","volume":"11","author":"Munzone","year":"2026","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.005_bib137","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(25)00727-2","article-title":"Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study","volume":"27","author":"Shamai","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.09.005_bib138","article-title":"Development and validation of a multimodal clinical, pathologic, and genomic model for breast cancer recurrence. Preprint","author":"Nguyen","year":"2026","journal-title":"medRxiv"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2026.09.005_bib139","first-page":"GS01","article-title":"Abstract GS1-08: Multimodal artificial intelligence (AI) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILORx","volume":"32","author":"Sparano","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.005_bib140","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:47Z","timestamp":1793364287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":139,"alternative-id":["S0923753426066457"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive\/HER2-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}